Parallel Advisors’s Cardiol Therapeutics CRDL Stock Holding History

Parallel Advisors’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$32.3K	Buy	+19,464	New	+$31K	﹤0.01%	2472

Other funds holding CRDL

Integrity Alliance Urbandale, Iowa $3.28B AUM 15.79% 1-Year Est. Return

PVG Asset Management Golden, Colorado $147M AUM 52.72% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return

MGO One Seven Beachwood, Ohio $6.08B AUM 21.44% 1-Year Est. Return

Marble Harbor Investment Counsel Boston, Massachusetts $1.02B AUM 15.73% 1-Year Est. Return

Boyer Financial Services Newport Beach, California $125M AUM 9.98% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

BWG

Boomfish Wealth Group Alpharetta, Georgia $231M AUM 21.59% 1-Year Est. Return

APW

Aurora Private Wealth Rockaway, New Jersey $159M AUM 18.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Parallel Advisors's CRDL Position: Q3 2026 in Review

Parallel Advisors opened a new position in Cardiol Therapeutics (CRDL) in Q3 2026: 19,464 shares worth $32.3K. The stake represents ﹤0.01% of the portfolio and ranks #2472 among its holdings.

20 funds tracked by Wall St. Rank hold CRDL as of Q3 2026.

Parallel Advisors held 19,464 shares of Cardiol Therapeutics worth $32.3K as of Q3 2026.
Cardiol Therapeutics was a new Parallel Advisors position in Q3 2026.
Cardiol Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #2472 holding.
20 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.